Off-Label Ltd

subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link
subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link
subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link
subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link
subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link
subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link
subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link
subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link

US search results

Number of records found 19

Select ID for details Off-label therapeutic category Subcategory Drug Reported off-label use
33 Central Nervous System Behavioral Venlafaxine hydrochloride Treatment of children and adolescents (mean 9.9 years) with attention-deficit hyperactivity disorder (ADHD)
522 Central Nervous System Behavioral Venlafaxine hydrochloride Obsessive-compulsive disorder
2806 Central Nervous System Affective Venlafaxine hydrochloride High dose (375-600 mg/m2) therapy for the treatment of patients with major depressive disorder
3852 Central Nervous System Headache Venlafaxine hydrochloride Twelve week study to assess the prophylactic effect of venlafaxine in patients with migraine with or without aura
5483 Central Nervous System Anxiety Venlafaxine hydrochloride Randomized controlled trial to evaluate the efficacy of venlafaxine (37.5-300 mg daily as the extended release formulation) for the treatment of adult patients with a primary diagnosis of posttraumatic stress disorder
7351 Central Nervous System Headache Venlafaxine hydrochloride Randomized controlled trial to evaluate the efficacy of venlafaxine extended release (XR) (150 mg daily) for the prophylactic treatment of out-patients with tension-type headache and no current depression or anxiety disorders (The investigators conclude that this study provides preliminary evidence for the efficacy of venlafaxine XR in reducing the number of days with tension-type headache)
8105 Central Nervous System Hallucination Venlafaxine hydrochloride Case report of a seventy-eight year old woman with a history of mild depression and vision loss who experienced visual hallucinations characteristic of Charles Bonnet syndrome, that disappeared rapidly following treatment with venlafaxine (Although depression is an approved indication for venlafaxine, the investigators report that to their knowledge this is the first case to show that selective serotonin and noradrenalin reuptake inhibitors may be an effective treatment for visual hallucinations associated with vision loss)
8247 Central Nervous System Behavioral Venlafaxine hydrochloride Open label outpatient pilot study to explore the effects and pharmacodynamics of venlafaxine (0.5, 1.0 and 2.0 mg daily for two weeks) in thirty-eight children and adolescents with attention-deficit hyperactivity disorder (ADHD) (The investigators report that venlafaxine offered some benefit and appears to be relatively safe for the short term treatment of ADHD)
8912 Central Nervous System Somatoform Venlafaxine hydrochloride Open label trial to evaluate the efficacy of venlafaxine (Minimum dose 150 mg daily titrated until a therapeutic response was achieved and then maintained for eight weeks) in a total of seventeen patients with body dysmorphic disorder (The investigators report that the results of this limited investigation suggest that venlafaxine may be an effective treatment for body dysmorphic disorder, including both obsessive and compulsive symptoms; they conclude that additional controlled studies are warranted)
9067 Central Nervous System Somatoform Venlafaxine hydrochloride Randomized controlled trial to compare the efficacy and tolerability of mirtazapine with that of venlafaxine in a total of ninety-five patients with undifferentiated somatoform disorder (The investigators report that both mirtazapine and venlafaxine may be effective and well tolerated in the treatment of patients with undifferentiated somatoform disorder; further studies are required to allow more definite conclusions)
3770 Endocrine & Metabolic Menopause Venlafaxine hydrochloride Treatment of postmenopausal hot flushes (flashes) in otherwise healthy women
1328 Gastrointestinal & Liver Colon Venlafaxine hydrochloride Modulation of colonic sensorimotor functions in healthy adults (as an assessment of any potential role for venlafaxine in treating colonic disorders affecting motor and sensory functions)
7375 Malignant Disease Toxicity prophylaxis Venlafaxine hydrochloride Randomized controlled trial to evaluate the efficacy of clonidine (0.075 mg twice daily) and venlafaxine (37.5 mg twice daily) to reduce the frequency of hot flushes (flashes) in breast cancer patients for whom the use of hormone replacement therapy is contraindicated (The results of this four week study show that venlafaxine is significantly more effective than clonidine in reducing the frequency of hot flushes)
1903 Pain (incl neuropathy) Facial Venlafaxine hydrochloride Treatment of atypical face pain
3840 Pain (incl neuropathy) Neuropathic and neuropathy Venlafaxine hydrochloride Treatment of acute painful diabetic neuropathy (insulin neuritis) resulting in a rapid response in a diabetic patient who had undergone intensive insulin therapy following longstanding poor glycemic control
815 Pain (incl neuropathy) Postoperative Venlafaxine hydrochloride Perioperative administration to reduce the incidence of postmastectomy pain syndrome following breast cancer surgery (Extended release formulation of venlafaxine)
384 Pain (incl neuropathy) Unspecified chronic Venlafaxine hydrochloride Chronic pain of 'any etiology'
4996 Sexual Dysfunction Male Venlafaxine hydrochloride Pilot study to assess the efficacy of extended release venlafaxine (75 mg daily) as a therapy for the treatment of patients with premature ejaculation
838 Skin Microvasculature Venlafaxine hydrochloride Erythromelalgia

Definition of descriptors (where appropriate):

*The reported drug was used as part of a combined therapy regimen

SUBPOP Variability in response may represent responding/nonresponding patient subgroups
ALERT Potential for remarkable and/or significant toxicity

 

 

 

About Us |Privacy Policy | Contact Us | ©2008 Off-Label Ltd